Develops therapies for cardiopulmonary and fibrotic disorders that target underlying disease pathways to promote cellular repair and remodel or reverse fibrotic tissue. Aims to move beyond symptom management toward a new therapeutic standard of care, backed by a team experienced in pulmonary drug development and commercialization.